Medical network on December 19 - a line of second liver medicine prices by 55%.
The news of the entecavir price first caused a shock in hepatitis b patients group.
On December 6, said a hepatitis b patients, chongqing has bought after the price in the heavy medical FuEr yuan "entecavir" capsule, 0.5 x 7 mg of boxes of entecavir GanDing (grace) capsule carton dropped to 63.08 yuan.
Zhengzhou university first affiliated hospital of infectious diseases department chief physician professor zu-jiang yu once wrote, oral drug entecavir is hepatitis b a best of antiviral drug resistance (lowest risk), the ability to suppress the virus than adefovir nearly 10 times above, so is suitable for all viral load of different people, the majority of patients can rapid turn within 6 months, so the strongest ability to control the disease.
First-line drugs and for current resistance problem generally, entecavir is the lowest all antiviral drug resistance, the least prone to virus, resistance risk is only 1.2%, 6 years are very encouraging.
But accordingly, entecavir and corresponding price is relatively high at present, although in recent years because of generics companies and enter more reimbursement list prices fell, but the need for long-term medication, still there is a big economic pressure.
Have patients, said he before taking some brand 0.5 mg x 7 carton of entecavir capsule, prescribe medicine from the hospital and a box of 140 yuan, eat every day 1 grain, eat four boxes, one month a year to spend 6720 yuan; After the price, the same name, the same value, which is the same manufacturer after drugs dropped to 63.08 yuan, can save 3692 yuan a year.
Not only that, it is reported, including entecavir (s) : the scattered pieces of different dosage forms, such as, medicine by price adjustment in chongqing, this also has different degree of decline, after adjustment, the drug price is lower than the provincial the average price, with the lowest price in fujian province.
Not in place of "price"
In 2010, chongqing was established in the country the first drug exchange, to become the nation's first third party medicine, the whole process of public electronic trading platform, establishing pharmaceutical circulation mechanism, reduce drug transaction cost, promote the establishment of scientific and reasonable drug price formation mechanism, promote the rational regression such as drug prices is the purpose of its founding.
In 2014, chongqing medicine exchange regulatory commission issued by the chongqing drugs exchange drugs into the market price of dynamic adjustment method (revised) "notice, in which a regulation" special adjustment ", "to the listed product trading virtual actual transaction prices higher than market price, by the exchange regulatory commission related functional departments to study and exchange regulatory commission after investigation to verify process decision, exchange according to the rules of decision and the relevant adjustment into the market."
And, according to news reports quoted entecavir capsules from November 140 yuan each to now priced at $63.08 price, it is because of chongqing medicine pricing exchange intervention. Yet entecavir, chongqing, the actual sale price disparity still in the hospital.
Hepatitis b lung cancer three kinds of medicine prices by more than half
On May 20, the first batch of national drug price negotiation results publish to the society. Involves the first-line treatment for chronic hepatitis b drug tenofovir ester, ek non-small cell lung cancer targeted therapy drugs for the treatment and 3 kinds of drugs. Negotiations, according to the results compared with public hospitals before purchase price, the three to negotiate drug prices more than halved, with neighboring countries (area) convergence.
Among them, the first-line treatment for chronic hepatitis b drug tenofovir ester talks after the price compared with public hospitals before purchasing price drop of 67%, non-small cell lung cancer targeted therapy drugs for ek, the treatment and reduction of 54%, 54% respectively.
This news for chronic hepatitis b patients and in patients with non-small cell lung cancer is the Gospel. This means that their medical expenses burden will be greatly reduced. This system is also considered adjustment of public administration needs innovation and practical ability to pay.
On "how to solve the patent medicine, imported drugs are expensive, people can't afford to use medicine", the national health and family planning commission director Li Binceng foreign said, is taking measures such as "national negotiations" strive to lower the price of patent medicine, imported drugs.
, according to people familiar with the countries of China, has become the world's largest liver disease to entecavir such first-line drugs into national or local price negotiation system is must. |
